文献速递心律失常

皮下植入式心律转复除颤器植入后心室颤动转复测试:来自国家心血管数据登记的报告

Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry.
PubMed 文献 · Circulation · 2018-02-20

该研究基于美国国家心血管数据登记ICD登记,分析2012年9月28日至2016年4月1日首次接受S-ICD的7960例患者,发现70.7%进行了心室颤动转复测试,测试使用更多由中心偏好驱动而非患者因素,且与院内并发症或死亡复合终点无关联;无既往ICD的4864例中6.9%出现转复能量>65J的安全边际不足。

要点

  • S-ICD植入后转复测试使用率70.7%,中心效应比患者因素更重要。
  • 无既往ICD患者中6.9%出现转复能量>65J的安全边际不足。
  • 转复测试与院内并发症或死亡复合终点无关联。

核心结论

  • S-ICD植入后转复测试的使用更多由中心偏好驱动而非患者因素,且与院内并发症或死亡复合终点无关联。
  • 安全边际不足相对少见,并与若干常规可得的患者特征相关,这些数据可能有助于ICD系统选择和靶向转复测试。

研究设计与样本

  • 研究为基于美国国家心血管数据登记ICD登记的分析,纳入2012年9月28日至2016年4月1日首次接受S-ICD的患者共7960例。
  • 使用多变量logistic回归预测转复测试使用和安全边际不足,使用逆概率加权logistic回归分析转复测试与院内不良事件的关联。

主要发现

  • 7960例S-ICD患者中70.7%(n=5624)进行了转复测试。
  • 转复测试的延迟与多个患者特征相关,包括体重指数升高、体表面积增大、射血分数严重降低、透析依赖、华法林使用、贫血和肥厚型心肌病,但中心效应相对更重要(患者水平AUC 0.619 vs 广义线性混合模型AUC 0.877)。
  • 无既往ICD的4864例患者中6.9%(n=336)出现安全边际不足,定义为心室颤动转复能量>65J。
  • 安全边际不足在白人患者、植入前心电图有心室起搏、植入前血压较高、体表面积较大、体重指数较高和射血分数较低者中更常见。
  • 风险评分可识别安全边际不足低风险(<5%)、中风险(5%至10%)和高风险(>10%)患者。

关键数值与推荐

  • 安全边际不足定义为心室颤动转复能量>65J。
  • S-ICD最大设备输出为80J。
  • 风险评分分层:低风险<5%,中风险5%至10%,高风险>10%。

临床怎么用

  • S-ICD植入后转复测试的使用应关注中心偏好差异,而非仅基于患者因素。
  • 可利用常规患者特征和风险评分识别安全边际不足高风险患者,以指导靶向转复测试。
  • 转复测试与院内并发症或死亡无关联,支持其安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Compared with transvenous implantable cardioverter defibrillators (ICDs), subcutaneous (S)-ICDs require a higher energy for effective defibrillation. Although ventricular fibrillation conversion testing (CT) is recommended after S-ICD implantation to ensure an adequate margin between the defibrillation threshold and maximum device output (80J), prior work found that adherence to this recommendation is declining. METHODS: We studied first-time recipients of S-ICDs (between September 28, 2012, and April 1, 2016) in the National Cardiovascular Database Registry ICD Registry to determine predictors of use of CT, predictors of an insufficient safety margin (ISM, defined as ventricular fibrillation conversion energy >65J) during testing, and inhospital outcomes associated with use of CT. Multivariable logistic regression analysis was used to predict use of CT and ISM. Inverse probability weighted logistic regression analysis was used to examine the association between use of CT and inhospital adverse events including death. RESULTS: CT testing was performed in 70.7% (n=5624) of 7960 patients with S-ICDs. Although deferral of CT was associated with several patient characteristics (including increased body mass index, increased body surface area, severely reduced ejection fraction, dialysis dependence, warfarin use, anemia, and hypertrophic cardiomyopathy), the facility effect was comparatively more important (area under the curve for patient level versus generalized linear mixed model: 0.619 versus 0.877). An ISM occurred in 6.9% (n=336) of 4864 patients without a prior ICD and was more common among white patients and those with ventricular pacing on the preimplant ECG, higher preimplant blood pressure, larger body surface area, higher body mass index, and lower ejection fraction. A risk score was able to identify patients at low (<5%), medium (5% to 10%), and high risk (>10%) for ISM. CT testing was not associated with a composite of inhospital complications including death. CONCLUSIONS: Use of CT testing after S-ICD implantation was driven by facility preference to a greater extent than patient factors and was not associated with a composite of inhospital complications or death. ISM was relatively uncommon and is associated with several widely available patient characteristics. These data may inform ICD system selection and a targeted approach to CT.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Friedman DJ, Parzynski CS, Heist EK, et al. Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry. Circulation. 2018. PMID: 29463509. doi:10.1161/CIRCULATIONAHA.117.032167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。